286 related articles for article (PubMed ID: 37482564)
1. Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice.
Gooderham MJ; Pink AE; Simpson EL; Silverberg JI; Güler E; Watkins M
Dermatol Ther (Heidelb); 2023 Sep; 13(9):1893-1907. PubMed ID: 37482564
[TBL] [Abstract][Full Text] [Related]
2. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K; Silverberg JI; Papp KA; Deleuran M; Katoh N; Strober B; Beck LA; de Bruin-Weller M; Werfel T; Zhang F; Biswas P; DiBonaventura MD; Chan G; Johnson S; Farooqui SA; Kerkmann U; Clibborn C
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2056-2066. PubMed ID: 37335885
[TBL] [Abstract][Full Text] [Related]
3. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
Thyssen JP; Bewley A; Ständer S; Castro C; Misery L; Kim BS; Biswas P; Chan G; Myers DE; Watkins M; Alderfer J; Güler E; Silverberg JI
Dermatology; 2024; 240(2):243-253. PubMed ID: 38081155
[TBL] [Abstract][Full Text] [Related]
4. Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
Reich K; Silverberg JI; Papp KA; Deleuran M; Katoh N; Strober B; Beck LA; de Bruin-Weller M; Werfel T; Zhang F; Biswas P; DiBonaventura MD; Chan G; Farooqui SA; Kerkmann U; Clibborn C
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2047-2055. PubMed ID: 37319109
[TBL] [Abstract][Full Text] [Related]
5. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes.
Cork MJ; McMichael A; Teng J; Valdez H; Rojo R; Chan G; Zhang F; Myers DE; DiBonaventura M
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):422-433. PubMed ID: 34743361
[TBL] [Abstract][Full Text] [Related]
6. Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives.
Niculet E; Bobeica C; Stefanopol IA; Pelin AM; Nechifor A; Onisor C; Tatu AL
Ther Clin Risk Manag; 2022; 18():399-407. PubMed ID: 35444421
[TBL] [Abstract][Full Text] [Related]
7. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
8. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
Alexis A; de Bruin-Weller M; Weidinger S; Soong W; Barbarot S; Ionita I; Zhang F; Valdez H; Clibborn C; Yin N
Dermatol Ther (Heidelb); 2022 Mar; 12(3):771-785. PubMed ID: 35297025
[TBL] [Abstract][Full Text] [Related]
9. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop KL; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Zhang M; Farooqui SA; Romero W; Thorpe AJ; Rojo R; Johnson S
Am J Clin Dermatol; 2021 Sep; 22(5):693-707. PubMed ID: 34406619
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
[TBL] [Abstract][Full Text] [Related]
12. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial.
Flohr C; Cork MJ; Ardern-Jones MR; Eichenfield LF; Barbarot S; Feeney C; Rojo R; Lazariciu I; Nesnas J
J Dermatolog Treat; 2023 Dec; 34(1):2200866. PubMed ID: 37036183
[TBL] [Abstract][Full Text] [Related]
14. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
Blauvelt A; Silverberg JI; Lynde CW; Bieber T; Eisman S; Zdybski J; Gubelin W; Simpson EL; Valenzuela F; Criado PR; Lebwohl MG; Feeney C; Khan T; Biswas P; DiBonaventura M; Valdez H; Cameron MC; Rojo R
J Am Acad Dermatol; 2022 Jan; 86(1):104-112. PubMed ID: 34416294
[TBL] [Abstract][Full Text] [Related]
15. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents.
Ständer S; Bhatia N; Gooderham MJ; Silverberg JI; Thyssen JP; Biswas P; DiBonaventura M; Romero W; Farooqui SA
J Eur Acad Dermatol Venereol; 2022 Aug; 36(8):1308-1317. PubMed ID: 35462428
[TBL] [Abstract][Full Text] [Related]
16. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life.
Blauvelt A; Boguniewicz M; Brunner PM; Luna PC; Biswas P; DiBonaventura M; Farooqui SA; Rojo R; Cameron MC
J Dermatolog Treat; 2022 Aug; 33(5):2605-2613. PubMed ID: 35763326
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
Eichenfield LF; Flohr C; Sidbury R; Siegfried E; Szalai Z; Galus R; Yao Z; Takahashi H; Barbarot S; Feeney C; Zhang F; DiBonaventura M; Rojo R; Valdez H; Chan G
JAMA Dermatol; 2021 Oct; 157(10):1165-1173. PubMed ID: 34406366
[TBL] [Abstract][Full Text] [Related]
18. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M
Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).
Shi VY; Bhutani T; Fonacier L; Deleuran M; Shumack S; Valdez H; Zhang F; Chan GL; Cameron MC; Yin NC
J Am Acad Dermatol; 2022 Aug; 87(2):351-358. PubMed ID: 35439608
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of abrocitinib compared with standard of care in adult moderate-to-severe atopic dermatitis in Japan.
Tanaka A; Yuasa A; Kamei K; Nagano M; Murofushi T; Bjerke A; Nakamura K; Ikeda S
J Dermatol; 2024 Jun; 51(6):759-771. PubMed ID: 38650307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
